XENON PHARMACEUTICALS INC.
Income Statement
| Line Item | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|
| Revenue | $1.8M | $15.6M | $28.4M | $27.4M | $14.3M |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | $19.8M | $15.2M | $11.8M | $12.3M | $10.5M |
| SG&A Expense | $6.8M | $9.8M | $5.5M | $5.3M | $7.0M |
| Operating Income | $-24.8M | $-9.4M | $11.1M | $9.7M | $-3.2M |
| Operating Margin | -1,376.4% | -60.1% | 39.1% | 35.5% | -22.0% |
| Interest Expense | — | — | — | $64.0K | $93.0K |
| Pretax Income | — | — | — | — | — |
| Income Tax Expense | — | — | $0 | $0 | $0 |
| Net Income | $-23.0M | $-15.8M | $13.0M | $12.0M | $-4.3M |
| Net Margin | -1,275.5% | -101.1% | 45.9% | 44.0% | -30.1% |
| EPS (Basic) | $-1.48 | $-1.10 | $1.03 | $0.72 | $-0.81 |
| EPS (Diluted) | $-1.48 | $-1.10 | $0.82 | $0.48 | $-0.81 |
| Shares Outstanding (Basic) | 15.5M | 14.3M | 12.7M | 5.4M | 5.3M |
| Shares Outstanding (Diluted) | 15.5M | 14.3M | 15.9M | 8.0M | 5.3M |
| Dividends Per Share | — | — | — | — | — |